Markets

NeuroRx, Inc., in partnership with Relief Therapeutics Holdings AG (OTC:RLFTF, SIX:RLF) today announced that the independent Data Monitoring Committee has reviewed the findings in the first 30 patients treated in Fast Track FDA trials of RLF-100 (Aviptadil) in patients with Critical COVID-19 with respiratory failure. The study protocol enrolls patients with Critical COVID-19 and Respiratory Failure and randomly assigns them to intravenous RLF-100 or Placebo in the hopes of achieving remission from this most-serious stage of COVID-19. At the committee’s recommendation, the primary endpoint is changed to “alive and free of respiratory failure at 7-10 days.” This change in primary endpoint from mortality at 28 days is driven by the general decrease in mortality with advances in treatment for Critical COVID-19 and by initial observations in the clinical trial. This first interim analysis was focused on verifying the apparent safety of the drug in the first 30 patients and the feasibility of the study to reach its endpoint. The committee determined that the study appeared capable of reaching a statistically significant endpoint within its 144 patient sample size and voted for the study to continue until its next scheduled evaluation in four weeks. The committee is composed

Raven Industries, Inc. (the Company; NASDAQ:RAVN) announced today that its Engineered Films Division has received a $4.8 million contract award from the Federal Emergency Management Agency (FEMA) for the delivery of film-based medical supplies. The contract includes delivery of medical supplies to various state and local organizations for their support with COVID-19 related matters. “We are honored for the opportunity to leverage our innovations and unique products in assisting with the ongoing efforts related to COVID-19,” said Dan Rykhus, President and Chief Executive Officer of Raven Industries. “Utilizing our technology in reinforced materials and custom fabrication, we were well-positioned to win this contract.” Rykhus went on to say, “We continue to pursue and secure contracts of this nature because of our agility and strong commitment to solve great challenges.” The Company expects revenue from this contract to be mostly realized in the second and third quarters of this fiscal year. This unexpected volume helps offset lost volume in the Geomembrane market during the second quarter. About Raven Industries, Inc. Raven Industries (NASDAQ: RAVN) is dedicated to providing innovative, high-value products and solutions that solve great challenges throughout the world. Raven is a leader in precision

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced Pataday Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%), formerly prescribed as Pazeo®, has been approved by the Food and Drug Administration (FDA) for sale over-the-counter (OTC) in the United States. Pataday Once Daily Relief Extra Strength is the first and only once daily eye allergy itch drop offering a full 24 hours of relief without a prescription.1 Allergies are the sixth-leading cause of chronic illness in the U.S., generating approximately $2.7 billion in OTC retail sales.2,3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200714005390/en/ Pataday® Product Portfolio (Photo: Business Wire) “Alcon is thrilled to bring another needed innovation to the millions of people in the U.S. who suffer from itchy allergy eyes,” said Sergio Duplan, Region President of North America at Alcon. “With Pataday Once Daily Relief Extra Strength, eye allergy sufferers will get over-the-counter eye allergy itch relief that lasts a full 24 hours. We’re excited to bring more customer options to the Pataday product portfolio, which is already the number one eye allergy brand in the U.S. OTC market.” This formulation joins Pataday®

ConTe.it, a motor insurance brand, and Italian subsidiary of Admiral Group, and Guidewire Software, Inc. (NYSE: GWRE), the platform general insurers trust to engage, innovate, and grow efficiently, today announced that ConTe.it has selected additional Guidewire Core and Data products. ConTe.it has now chosen Guidewire ClaimCenter for its claims management system, and Guidewire DataHub for its enterprise-wide data management capabilities. The insurance brand plans to replace their existing systems, using Agile methodology, over a two-year period. “Following our successful deployments of PolicyCenter and BillingCenter, we are comfortable in our selection of Guidewire as a reliable vendor in the claims management space,” said Paolo Rozzi, Head of Claims at ConTe.it. “ClaimCenter will help us in reducing claim cycle times and utilising more data and analytics effectively in our claims operations. It is a good complement to our other Guidewire products which, combined, will help us provide better overall service to our customers.” The increased use of Guidewire products will enable ConTe.it to: Enhance efficiency, productivity, and scalability by integrating their claims operations more fully with their policy administration and billing systems; Gather data more easily and systematically for better reporting and control; and Execute on its customer service

Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic patient care services and solutions, today announced it will report its financial results for the second quarter and six months ended June 30, 2020 after the stock market closes on Wednesday, Aug. 5, 2020. Hanger’s management team will host a conference call with the financial community to discuss the financial results the following morning on Thursday, Aug. 6 at 8:30 a.m. Eastern time. A live webcast, replay of the call and earnings release, will be available on the Company’s Investor Relations website: investor.hanger.com/financial-reporting. For members of the financial community participating in the conference call: dial 866-270-1533, or 412-317-0797 outside the U.S. and Canada, and ask to be joined into the Hanger, Inc. call. About Hanger, Inc. – Hanger, Inc. (NYSE: HNGR) delivers orthotic and prosthetic (O&P) patient care, and distributes O&P products and rehabilitative solutions to the broader market. Hanger’s Patient Care segment is the largest owner and operator of O&P patient care clinics with approximately 800 locations nationwide. Through its Products & Services segment, Hanger distributes branded and private label O&P devices, products and components, and provides rehabilitative solutions. With nearly 160 years of

Northern Trust (Nasdaq: NTRS) has further expanded its market footprint across the global insurance sector with three new mandates from European-based insurers. Northern Trust will provide a broad range of asset servicing solutions to Hannover Re, Aioi Nissay Dowa Insurance (AND-E) and the Medical and Dental Defence Union of Scotland (MDDUS). These clients appointed Northern Trust in the first quarter of 2020 and were on-boarded before the end of June. “Northern Trust continues to actively grow its insurance and re-insurance client base across the globe,” said Mark Austin, head of UK, Institutional Investor Group, Northern Trust. “Our history of financial stability, expertise and continuous investment in technology strongly aligns with insurance companies’ requirements for heightened efficiency, transparency and risk management across their investments. These appointments, which add to our significant relationships with many of the world’s leading insurance organizations, highlight our experience of the industry and how we work with insurers to help them execute their business strategies.” Hannover Re is one of the world’s largest reinsurers, with a gross written premium of more than €22 billion as of 31 December 2019. Northern Trust is providing the Germany-headquartered company with collateral management services for its longevity risk

Turning Point Brands, Inc. (“TPB” or the “Company”) (NYSE: TPB), a leading provider of Other Tobacco Products (“OTP”) and adult consumer alternatives, today announced preliminary sales results for the second quarter ended June 30, 2020 in connection with the underwritten secondary offering by certain of its stockholders of 2,000,000 shares of TPB’s common stock. TPB plans to release its full second quarter 2020 financial results along with updated full year guidance on July 28, 2020. During the second quarter of 2020, the Company delivered strong execution of its business strategy and achieved record quarterly net sales. Preliminary estimates of net sales exceeded $100 million for the second quarter of 2020 compared to net sales guidance of $81 to $87 million provided on April 28, 2020. All segments outperformed management expectations for the second quarter of 2020. In the Smokeless segment, the secular consumer down-trading trends that accelerated earlier in the year continued during the quarter as the Stoker’s MST line continues to build momentum and gain consumer acceptance. In the Smoking segment, sales benefitted from increased consumption, new product penetration and recently implemented growth initiatives which offset the COVID-related supply chain disruption experienced in the MYO cigar wraps

With the project “Proud to share” Team Trecento11 secured the victory of the 2020 edition of the Creative Challenge, the largest competition in Europe for students and young creatives organized by Reply and part of the online team-based series of competitions, Reply Challenges. Launched last May 22nd with the online qualification marathon (running 48h), the challenge gathered over 6,200 creative talents (+77% vs. 2019 edition) from more than 70 countries around the World to focus their creative efforts on five categories: Employer Branding, Brand Activation, Service Design, Branded Content and Social Media:Instagram. Spread across over 1,000 teams, the young talents – with an average age between 18 and 29 – put their skills and personalities into the development of a creative concept based on a brief assigned by some of the most renowned marketing and communication professionals in Europe. This year’s challenge was characterized by the need to rethink consumer engagement strategies to respond to the spread of the pandemic. During the development of the projects explicit references to the events of the past few months were made, with numerous proposals focused on the restart. Of the 500+ proposals submitted it was the projects “Proud to

KKR, a leading global investment firm, today announced the appointment of Simon Marrison as a Senior Advisor, effective Sept 7th 2020. In his role, Mr. Marrison will advise KKR on real estate investments across Europe and help contribute to the growth of KKR’s real estate business in the region. Mr. Marrison will retire as Chairman of LaSalle Investment Management’s European business in July, after a 19-year career at the company, serving as CEO for Europe between 2007 and 2019, Head of Continental Europe from 2001 to 2007 and Chairman since July 2019. Prior to joining LaSalle, Mr. Marrison was Country Manager of Rodamco France. He is a member of the Royal Institution of Chartered Surveyors (RICS) and a member of the RICS Global Investment Risk Management Forum. Mr. Marrison has served as a Non-Executive Director of TR Property Investment Trust since 2011 and will become a Senior Independent Director in July. He holds a BSc. (Hons) in Urban Land Administration from Portsmouth Polytechnic. Ralph Rosenberg, Partner and Global Head of KKR Real Estate, and Guillaume Cassou, Partner and Head of KKR Real Estate Europe, said: “Simon has built an impressive track record in the real estate industry across

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that EVO Viva™, STAAR’s innovative presbyopia correcting implantable Collamer® lens (“ICL”), has been approved for sale. STAAR received CE Mark approval of the presbyopic indication for its EVO+ Visian® ICL with Aspheric (EDOF) Optic, commercially marketed as “EVO Viva”, from its European Notified Body, DEKRA, on July 2, 2020. EVO Viva will initially be available to patients through select eye doctors in Spain, Germany and Belgium. Broader availability of the lens will follow in Europe and other markets recognizing the CE Mark over the coming months. An introductory video highlighting EVO Viva’s market positioning for countries that accept the CE Mark is included with this press release. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200707005258/en/ “The launch of EVO Viva significantly expands the market opportunity for our EVO family of lenses to now include lenses for patients suffering from presbyopia in the over 30 countries that currently recognize the CE Mark,” said Caren Mason, President and CEO of STAAR Surgical. “EVO Viva is a new treatment option for potential future consideration by